» Articles » PMID: 35356811

High Prevalence of Undiagnosed Impaired Glucose Tolerance in Patients with Rheumatoid Arthritis

Overview
Journal SAGE Open Med
Publisher Sage Publications
Specialty General Medicine
Date 2022 Mar 31
PMID 35356811
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Although the risk of diabetes mellitus has been recognised in rheumatoid arthritis, undiagnosed dysglycaemia remained under-reported. The study aimed to determine the prevalence and associated factors of dysglycaemia among patients with rheumatoid arthritis, utilising the oral glucose tolerance test.

Methods: This cross-sectional study involved patients with rheumatoid arthritis, aged ⩾30 years. Following an oral glucose tolerance test, they were divided into two: dysglycaemia and normoglycaemia. Demographic and laboratory parameters were compared using logistic regression analyses.

Results: There were 35.5% (55/155) patients with dysglycaemia (including 25.8% impaired glucose tolerance, 7.1% diabetes mellitus and 1.9% with both impaired fasting glucose and impaired glucose tolerance). Patients with dysglycaemia were heavier (65.5 ± 12.3 versus 60.7 ± 10.6 kg, p = 0.01), had wider waist (89.0 ± 12.5 versus 83.1 ± 9.6 cm, p < 0.01), lower high-density lipoprotein cholesterol (1.4 ± 0.3 versus 1.5 ± 0.4 mmol/L, p = 0.02), higher triglyceride (1.3 (0.9-1.8) versus 0.9 (0.8-1.2) mmol/L, p < 0.01) and intercellular adhesion molecule-1 (361.79 (290.38-481.84) versus 315.92 (251.45-407.93) ng/mL, p = 0.01). History of smoking (odds ratio: 5.70, confidence interval: 1.27-25.7), elevated triglyceride (odds ratio: 2.87, confidence interval: 1.33-6.22) and intercellular adhesion molecule-1 (odds ratio: 1.003, confidence interval: 1.001-1.006) were significantly associated with dysglycaemia.

Conclusions: Prevalence of undiagnosed dysglycaemia, particularly impaired glucose tolerance, was high in these patients with rheumatoid arthritis, using a 75-g oral glucose tolerance test, which was not associated with disease activity or corticosteroid use. Those with high triglyceride, history of smoking and elevated intercellular adhesion molecule-1 were the two significant predictors for dysglycaemia in our patients with rheumatoid arthritis. Oral glucose tolerance test could be an important laboratory investigation for dysglycaemia in these high-risk patients.

Citing Articles

Rheumatoid arthritis, cardiometabolic comorbidities, and related conditions: need to take action.

Corrao S, Calvo L, Giardina A, Cangemi I, Falcone F, Argano C Front Med (Lausanne). 2024; 11:1421328.

PMID: 39114820 PMC: 11303151. DOI: 10.3389/fmed.2024.1421328.


Diabetes mellitus in rheumatic diseases: clinical characteristics and treatment considerations.

Fedorchenko Y, Mahmudov K, Abenov Z, Zimba O, Yessirkepov M Rheumatol Int. 2023; 43(12):2167-2174.

PMID: 37718369 DOI: 10.1007/s00296-023-05453-9.

References
1.
Zhang J, Fu L, Shi J, Chen X, Li Y, Ma B . The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS One. 2013; 8(10):e78151. PMC: 3808281. DOI: 10.1371/journal.pone.0078151. View

2.
van Steenbergen H, Huizinga T, van der Helm-van Mil A . The preclinical phase of rheumatoid arthritis: what is acknowledged and what needs to be assessed?. Arthritis Rheum. 2013; 65(9):2219-32. DOI: 10.1002/art.38013. View

3.
Aletaha D, Nell V, Stamm T, Uffmann M, Pflugbeil S, Machold K . Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005; 7(4):R796-806. PMC: 1175030. DOI: 10.1186/ar1740. View

4.
Hallajzadeh J, Safiri S, Mansournia M, Khoramdad M, Izadi N, Almasi-Hashiani A . Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis. PLoS One. 2017; 12(3):e0170361. PMC: 5363810. DOI: 10.1371/journal.pone.0170361. View

5.
Plenge R . Rheumatoid arthritis genetics: 2009 update. Curr Rheumatol Rep. 2009; 11(5):351-6. DOI: 10.1007/s11926-009-0050-0. View